Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Institute of Oncology), Milind Javle(The University of Texas MD Anderson Cancer Center), Robin Kate Kelley(University of California, San Francisco), Sam Joseph Lubner(University of Wisconsin Carbone Cancer Center), Jorge Adeva(Hospital Universitario 12 De Octubre), James M. Cleary(Dana-Farber Cancer Institute), Daniel V.T. Catenacci(University of Chicago Medical Center), Mitesh J. Borad(Mayo Clinic in Florida), John Bridgewater(University College London), William Proctor Harris(University of Washington), Adrian Murphy(Johns Hopkins University), Do‐Youn Oh(Seoul National University Hospital), Jonathan Whisenant(Utah Cancer Specialists), Maeve A. Lowery(Trinity College Dublin), Lipika Goyal(Massachusetts General Hospital), Rachna T. Shroff(University of Arizona), Anthony B. El-Khoueiry(University of Southern California), Bin Fan(Agios Pharmaceuticals (United States)), Bin Wu(Agios Pharmaceuticals (United States)), Christina X. Chamberlain(Agios Pharmaceuticals (United States)), Liewen Jiang(Agios Pharmaceuticals (United States)), Camelia Gliser(Agios Pharmaceuticals (United States)), Shuchi S. Pandya(Agios Pharmaceuticals (United States)), Juan W. Valle(The Christie NHS Foundation Trust), Andrew X. Zhu(Massachusetts General Hospital)
Cited by 1,057Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis